Inhibitor Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income dropped to -$3,026,135 over the previous period. Total operating expenses were $3,404,979.
Profit Margin
| 2014 | -26.49K | -3.97M | 15006.79% |
|---|---|---|---|
| 2015 | 0 | -3.94M | |
| 2016 | 0 | -7.00M | |
| 2017 | 0 | -5.10M | |
| 2018 | 0 | -4.55M | |
| 2019 | 0 | -2.71M | |
| 2020 | 0 | -1.05M | |
| 2021 | 0 | -313.46K | |
| 2022 | 0 | 12.10M | |
| 2023 | 0 | -3.02M |
INTI Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -26.49K |
Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -26.49K |
Operating exp. | ||||||||||
Research and development | 1.38M | 6.15K | 4.90K | 185.29K | 1.20M | 2.63M | 2.22M | 2.64M | 1.68M | 2.43M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 3.40M | 657.92K | 325.39K | 1.05M | 2.74M | 4.56M | 5.11M | 7.02M | 3.94M | 3.93M |
Operating income | -3.40M | -657.92K | -325.39K | -1.05M | -2.74M | -4.56M | -5.11M | -7.02M | -3.94M | -3.93M |
Other income (expenses), net | 378.84K | 12.81M | 26.76K | 1.06K | 14.54K | 14.02K | 17.86K | 21.98K | 0 | -37.48K |
Income before tax | -3.02M | 12.16M | -298.63K | -1.05M | -2.73M | -4.55M | -5.10M | -7.00M | -3.94M | -3.97M |
Income tax expense | 0 | 55.10K | 14.83K | -1.06K | -14.54K | -14.02K | -17.86K | -21.98K | -3.95K | -3.93K |
Net income | -3.02M | 12.10M | -313.46K | -1.05M | -2.71M | -4.55M | -5.10M | -7.00M | -3.94M | -3.97M |
Earnings per share | ||||||||||
Basic EPS | -0.02 | 0.03 | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.04 |
Diluted EPS | -0.01 | 0.03 | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.04 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |